All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21028NJ" target="_blank" >RIV/61988987:17110/20:A21028NJ - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11150/21:10415036 RIV/00216208:11120/21:43920575 RIV/00179906:_____/21:10415036 RIV/00098892:_____/21:N0000088 and 2 more

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.17074" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.17074</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/bjh.17074" target="_blank" >10.1111/bjh.17074</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

  • Original language description

    Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS-E) uses combination of absolute lymphocyte count (ALC) >15 x 10(9)/l, palpable lymphadenopathy, and unmutated immunoglobulin heavy-chain variable-region (IGHV)gene to predict the time to first-line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5-year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS-E score using an unselected, consecutive group of 130 Binet A patients. The 5-year TTFT was 11%, 36%, and 78% (C-statistic 0 center dot 74). Furthermore, we propose an alternative system (AIPS-E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5-year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5-year TTFT was 16%, 37%, and 80% (C-statistic 0 center dot 74). In conclusion, we have successfully validated the IPS-E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS-E, combiningIGHV, fluorescencein situhybridisation, and ALC.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    British Journal of Haematology

  • ISSN

    0007-1048

  • e-ISSN

  • Volume of the periodical

    193

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    5

  • Pages from-to

    133-137

  • UT code for WoS article

    000567704900001

  • EID of the result in the Scopus database